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Abstract
Introduction. Ivabradine is an agent that selectively decreases heart rate (depending on the dose) and does not affect 
other cardiovascular parameters. In particular, it does not influence left ventricular ejection fraction and does not in-
hibit vascular relaxation during exercise. Due to these properties, ivabradine can be used in those patients in whom 
beta-blockers are contraindicated or their dose escalation is not possible. These properties also suggest that use of 
ivabradine during cardiac rehabilitation in patients with contraindications to beta-blockers or beta-blocker intolerance 
might increase exercise tolerance. The aim of the study was to evaluate whether administration of ivabradine (in addi-
tion to or instead of beta-blockers) during a cardiac rehabilitation program improved exercise tolerance in comparison 
to patients receiving only beta-blockers.
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Material and methods
The study included patients treated with ivabradine and 
hospitalized in the Department of Cardiology at the Medical 
University of Lodz from December 2015 to August 2017. 
The study was retrospective and based on an analysis of 
the cardiac rehabilitation unit database. Due to retrospec-
tive nature of the study, which included only evaluation of 
patient medical records, ethics committee approval was 
not necessary.
The study group included 50 patients who fulfilled the 
following criteria: treatment with ivabradine, completion 
of the cardiac rehabilitation program with two exercise 
tests, on admission and at the end of hospitalization, and 
the presence of sinus rhythm. Table 1 shows the reasons 
for initiating ivabradine therapy in the study group. The 
control group included 50 patients who were not treated 
with ivabradine and was matched for age, gender, reason 
for admission to the cardiac rehabilitation unit, and con-
comitant conditions. Patients who did not complete the 
cardiac rehabilitation program or did not have two exercise 
Materials and methods. Fifty patients treated with ivabradine during cardiac rehabilitation were enrolled into this retro-
spective study. The control group was matched for gender, age and other comorbidities and consisted of 50 subjects. 
The improvement in exercise tolerance was compared between the group receiving beta-blockers alone and those on 
ivabradine treatment.
Results. The study included 100 patients — 60 males and 40 females. Our analysis of exercise test results expressed in 
metabolic equivalents of task (MET) suggested a positive effect of ivabradine on the improvement of exercise tolerance. 
The percentage improvement was significantly higher in patients on ivabradine compared to the control group (26.8% 
± 27.73% vs. 11.64% ± 19.34%, p = 0.002). In addition, a larger increase in the duration of exercise test was noted 
in patients treated with ivabradine (52.76% ± 47.29% vs. 32.59% ± 42.94%, p = 0.0101). No difference was found 
between patients who were already treated with ivabradine before cardiac rehabilitation and those in whom ivabradine 
was initiated during the cardiac rehabilitation program.
Conclusions. Treatment with ivabradine during a cardiac rehabilitation program was associated with a better improve-
ment in exercise tolerance compared to patients receiving beta-blockers alone.
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Table 1. Reasons for initiating ivabradine therapy in the study group
Reason Percentage [%]
Arrhythmia or conduction disturbances 16
Asthma or COPD 20
Hypotension 10




bpm — beats per minute; COPD — chronic obstructive pulmonary disease
Introduction
Advances in invasive cardiology techniques and drug thera-
py have resulted in a significant reduction of life years lost 
in patients with ischemic heart disease but also have led 
to an increase in the number of patients with chronic heart 
failure [1]. The quality of life of these patients is reduced, 
with difficulties encountered during routine daily activities. 
Thus, adequate rehabilitation should be planned follow-
ing successful treatment of an acute coronary syndrome 
(ACS) to allow the patient to return to normal activities as 
much as possible. The first step of rehabilitation should 
be initiated during the index hospitalization and this 
should be continued after hospital discharge as inpatient 
or outpatient cardiac rehabilitation [2]. Adequate cardiac 
rehabilitation reduces the risk of recurrent cardiovascular 
events, improves the quality of life, and prolongs life [2]. 
It is recommended in patients with stable coronary artery 
disease, following invasive treatment of ACS, and in chronic 
heart failure [3–6]. Drug therapy of these conditions in-
cludes beta-blockers which are well studied and effective 
medications but their benefits cannot be offered to all pa-
tients. Contraindications to beta-blockers include asthma, 
chronic obstructive pulmonary disease (COPD), symptoma-
tic bradycardia, and atrioventricular block. Even in patients 
without these conditions, however, beta-blockers may be 
poorly tolerated and cannot be used in adequate doses. 
In these situations, ivabradine is indicated for persisting 
sinus rhythm rate above 70 beats per minute. This novel 
drug selectively reduces heart rate and may be initiated 
also during cardiac rehabilitation. The aim of the study was 
to evaluate the effect of ivabradine on the improvement in 
exercise tolerance during a cardiac rehabilitation program.
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tests performed were excluded from the study. Overall, the 
analysis included 100 patients.
In all patients, a cardiac rehabilitation program was 
initiated according to the Polish Cardiac Society recom-
mendations [2]. An exercise test was performed on admis-
sion and at the end of hospitalization using the following 
protocols: Bruce protocol (66% of patients), modified 
Bruce protocol (21%), 25 W/3 min protocol using a cycle 
ergometer (10%), or Naughton protocol (3%).
Study data were analysed using the STATISTICA 13 pack-
age (StatSoft Inc., USA). Continuous variables were 
expressed as mean values ± standard deviation, and ca-
tegorical variables as numbers and percentages. Normal 
distribution of the evaluated quantitative variables was 
assessed using the Shapiro-Wilk W test. Study groups 
were compared using the Student t test (or nonparame-
tric Mann-Whitney test, depending on data distribution) 
or chi-square test (or exact Fisher test). More than two 
variables with normal distribution and equal variances 
were compared using ANOVA, and the Kruskal-Wallis test 
was used if otherwise and for categorical variables. For all 
analyses, p < 0.05 was considered statistically significant.
Results
Overall, we analysed a group of 40 women and 60 men 
aged 41–86 years. The most common reason for admission 
to a cardiac rehabilitation unit was previous myocardial 
infarction (39%). Other reasons were heart failure (11%), 
previous coronary artery bypass grafting (29%), unstable 
coronary artery disease (11%), and previous implantation 
of a valve prosthesis (10%). Common concomitant condi-
tions were hypertension (85%) and diabetes type 2 (38%). 
Detailed characteristics of the study and control groups 
are shown in Table 2.
In our study, we investigated in detail results of the 
exercise tests expressed in metabolic equivalents of task 
(METs), which allow evaluation of the intensity of exercise. 
The reason for terminating the exercise test was patient 
fatigue (76%) or achieving target heart rate (24%). Exercise 
tolerance on admission was slightly lower in patients trea-
ted with ivabradine compared to the control group (5.71 ± 
± 2.37 MET vs. 6.13 ± 2.50 MET, p = 0.43). At the end 
of hospitalization, exercise tolerance was slightly higher 
in the study group compared to the control group but the 
difference was not significant (7.11 ± 3.11 MET vs. 6.76 ± 
± 2.74 MET, p = 0.89). The analysis of both exercise tests 
suggest a positive effect of ivabradine on the improve-
ment in exercise tolerance during cardiac rehabilitation 
(p = 0.004, Figure 1).
A percentage change in exercise tolerance during ho-
spitalization in relation to the result of the first exercise 
test was calculated using the formula:
ext2/ext1 × 100% = ∆ext
where ext2 is exercise tolerance in METs during the 
exercise test at the end of hospitalization, ext1 is exercise 
tolerance in METs during the initial exercise test, and ∆ext 
is the percentage change in exercise tolerance in METs.
Our analysis of this parameter indicated a significantly 
higher percentage change in exercise tolerance in patients 
treated with ivabradine (26.8 ± 27.73 vs. 11.64 ± 19.34; 
p = 0.002; Figure 2).
When we compared patients in whom ivabradine was 
initiated during the cardiac rehabilitation program with tho-
se who were treated with ivabradine before hospitalization, 
Table 2. Characteristics of the study and control groups
Study group Control group
Gender Women 20 20 p = 1 (NS)
Men 30 30
Age 63.26 ± 10.35 63.04 ± 10.84 p = 0.89 (NS)
SBP [mm Hg] 129.22 ± 18.42 130.69 ± 11.92 p = 0.49 (NS)
DBP [mm Hg] 77.46 ± 9.93 78.53 ± 9.31 p = 0.34 (NS)
Left ventricular ejection fraction [%] 70.74 ± 11.17 65.23 ± 11.09 p = 0.08 (NS)
Previous myocardial infarction treated percutaneously 20 19
Heart failure 7 4
Previous coronary artery bypass grafting 10 19 p = 0.30 (NS)
Unstable angina treated percutaneously 7 4
Prosthetic valve implantation 6 4
Diabetes type 2 22 16 p = 0.21 (NS)
Hypertension 42 43 p = 0.78 (NS)
NS — not significant; SBP — systolic blood pressure; DBP — diastolic blood pressure
}
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we did not found significant differences in the improvement 
in exercise tolerance (p = 0.366, Figure 3).
Another important indicator of exercise tolerance is the 
duration of exercise test. Before cardiac rehabilitation, it 
was on average 4 minutes 51.6 seconds in patients treated 
with ivabradine compared to 4 minutes 33.6 seconds in 
the control group. At the end of the cardiac rehabilitation 
program, these durations were 6 minutes 50 seconds 
and 5 minutes 37 seconds, respectively. Our analysis of 
the percentage increase in the duration of exercise test 
suggests a beneficial effect of ivabradine on the improve-
ment in exercise tolerance (52.76% ± 47.29 vs. 32.59% 
± 42.94, p = 0.0101, Figure 4).
Discussion
The most important result of our study is an observation 
that in patients receiving ivabradine during cardiac re-
habilitation, either as the main medication to slow down 
the heart rate or in combination with a beta-blocker, the 
improvement in exercise tolerance is better compared to 
patients with similar demographic and clinical characteri-
stics who received only beta-blockers.
Ivabradine selectively reduces heart rate by blocking 
the pacemaker current If in the sinus node. This drug only 
affects slow resting polarization without an effect on other 
cardiovascular system function parameters [7]. In parti-
cular, it does not affect the refraction period and cardiac 
conduction velocity [8], inotropic effect [9], left ventricular 
systolic function [9], coronary vessel contractility [9], left 
ventricular ejection fraction [10], and peripheral resistance. 
These characteristics indicate that ivabradine is an inte-
resting alternative to beta-blockers that also affect other 
cardiovascular parameters in addition to the effect on the 
heart rate. Both beta-blockers and ivabradine improve exer-
cise tolerance and reduce the frequency of anginal attacks 
Figure 1. Improvement in exercise tolerance in the study and con-
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Figure 2. Percentage change in exercise tolerance during cardiac 
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Figure 3. Comparison of the improvement in exercise tolerance in 
patients treated with ivabradine before cardiac rehabilitation and 





















Figure 4. Percentage change in the duration of exercise test at the 
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but in contrast to beta-blockers, ivabradine does not effect 
myocardial contractility, atrioventricular conduction, and 
coronary adaptation to exercise. Ivabradine may be used in 
patients with reduced beta-blocker tolerance or when use of 
these drugs or their dose escalation is not recommended, 
for example due to asthma or cardiac conduction abnor-
malities. Amosova et al. [11] showed that administration 
of ivabradine instead of an increase in bisoprolol dose in 
patients with stable angina improved exercise tolerance (as 
measured by the 6-minute walking test and exercise test) 
and increased chronotropic reserve. Similar properties of 
ivabradine were shown by Bagriy et al. [12] in a prospective 
study that evaluated the effects of initiating this medication 
in patients with systolic heart failure who were treated with 
carvedilol. Patients who received an If current inhibitor had 
slower resting heart rate, higher ejection fraction, and im-
proved exercise tolerance. These studies indicate that drug 
treatment with ivabradine seems safe in subjects with redu-
ced exercise tolerance and suggest it may be used during 
cardiac rehabilitation with the aim of improving the quality of 
life by increasing exercise capacity. Our study confirmed that 
administration of ivabradine to patients undergoing a car-
diac rehabilitation program increased exercise tolerance as 
measured in METs and increased the duration of exercise 
compared to patients treated only with beta-blockers. Our 
results are in agreement with other studies that evaluated 
the effectiveness of beta-blocker and ivabradine therapy 
during cardiac rehabilitation. Marazia et al. [13] showed 
that in patients undergoing cardiac rehabilitation following 
coronary artery bypass grafting, addition of ivabradine to 
bisoprolol improved exercise capacity, resulted in an earlier 
recovery of systolic function, and reduced diastolic dysfun-
ction. Few reports are available on the use of an If current 
inhibitor during cardiac rehabilitation following an acute 
coronary syndrome. In our study, we focused on evaluating 
patients who were matched for concomitant conditions, 
age, and resting heart rate. Future studies should evaluate 
whether the improvement in exercise tolerance is similar in 
patient with different specific cardiac conditions.
Conclusions
In patients receiving ivabradine during cardiac rehabilita-
tion, either as the main medication to slow down the heart 
rate or in combination with a beta-blocker, the improvement 
in exercise tolerance is better compared to patients with 
similar demographic and clinical characteristics who were 
treated only with beta-blockers.
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Streszczenie
Wstęp. Iwabradyna jest substancją wybiórczo zmniejszającą częstotliwość rytmu serca (zależnie od dawki), nie wpływa-
jąc jednocześnie na inne parametry układu sercowo-naczyniowego. W szczególności nie wpływa na frakcję wyrzutową 
lewej komory ani nie hamuje wysiłkowego rozkurczu naczyń. Dzięki tym właściwości można ją zastosować u chorych, 
u których podawanie beta-adrenolityków jest przeciwwskazane. Opisane właściwości sugerują, że włączenie iwabradyny 
podczas rehabilitacji kardiologicznej u pacjentów, u których występują przeciwwskazania do leczenia beta-adrenolityka-
mi lub do zwiększenia ich dawki, może usprawnić tę rehabilitację i w efekcie zwiększyć tolerancję wysiłkową.
Celem opisanego badania był ocena, czy włączenie iwabradyny podczas rehabilitacji kardiologicznej wpływa na zwięk-
szenie osiąganej tolerancji wysiłkowej w porównaniu z pacjentami otrzymującymi jedynie beta-adrenolityki.
Materiały i metody. Pięćdziesięciu pacjentów, leczonych iwabradyną i hospitalizowanych na Oddziale Rehabilitacji Kar-
diologicznej Wojewódzkiego Specjalistycznego Szpitala im. dr. Władysława Biegańskiego w Łodzi, zakwalifikowano do 
retrospektywnego badania. Grupę kontrolną dopasowano pod względem płci, wieku oraz innych chorób towarzyszących 
i składała się z 50 pacjentów leczonych zgodnie z wytycznymi. Analizowano związek między przyjmowaniem iwabradyny 
a tolerancją wysiłku fizycznego.
Wyniki. W badaniu wzięło udział 100 pacjentów — 60 mężczyzn i 40 kobiet. Analiza wyników testu wysiłkowego wy-
rażonych w ekwiwalentach metabolicznych (MET) sugeruje korzystny wpływ iwabradyny na poprawę tolerancji wysiłku 
fizycznego. Procentowa poprawa była wyższa w grupie badanej niż w grupie kontrolnej (26,8% ± 27,73% v. 11,64% ± 
± 19,34%; p = 0,002). Odnotowano również istotne wydłużenie czasu trwania próby wysiłkowej u pacjentów przyjmujących 
iwabradynę (52,76% ± 47,29% v. 32,59% ± 42,94%; p = 0,0101). Nie stwierdzono związku między pacjentami, którzy 
przyjmowali iwabradynę przed hospitalizacją, a pacjentami, którzy rozpoczęli terapię iwabradyną w trakcie rehabilitacji.
Wnioski. Pacjenci otrzymujący iwabradynę w procesie rehabilitacji kardiologicznej osiągają lepszą tolerancję wysiłku niż 
pacjenci otrzymujących jedynie beta-adrenolityki.
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